Approach to the Patient With a Suboptimal Statin Response: Causes and Algorithm for Clinical Management

• Published in: The journal of clinical endocrinology and metabolism Vol. 108; no. 9; pp. 2424 - 2434
• Main Authors: Sun, Lufan, Wolska, Anna, Amar, Marcelo, Zubirán, Rafael, Remaley, Alan T
• Format: Journal Article
• Language: English
• Published: US Oxford University Press 18.08.2023
• Subjects: Algorithms; Approach To The Patient; Arteriosclerosis; Cardiovascular disease; Cardiovascular diseases; Cholesterol; Drug metabolism; Genetic diversity; Genetic screening; Hypercholesterolemia; Lipid metabolism; Lipids; Lipoproteins; Low density lipoprotein; Pharmacokinetics; Statins; cardiovascular disease; cholesterol; statin resistance; statins; lipoproteins; patient management
• ISSN: 0021-972X; 1945-7197
• DOI: 10.1210/clinem/dgad153

Abstract Context Statins are the lipid-lowering therapy of choice for the prevention of atherosclerotic cardiovascular disease (ASCVD) but their effectiveness in lowering low-density lipoprotein cholesterol (LDL-C) can substantially differ between individuals. In this mini-review, we describe the different causes for a suboptimal statin response and an algorithm for the diagnosis and clinical management of these patients. Evidence Acquisition A PubMed search using the terms “statin resistance,” “statin sensitivity,” “statin pharmacokinetics,” “cardiovascular disease,” and “lipid-lowering therapies” was performed. Published papers in the past 10 years that were relevant to the topic were examined to provide content for this mini-review. Evidence Synthesis Suboptimal lowering of LDL-C by statins is a major problem in the clinical management of patients and limits the value of this therapeutic approach. There are multiple causes of statin hyporesponsiveness with compliance being the most common explanation. Other causes, such as analytical issues with LDL-C measurement and the presence of common lipid disorders (familial hypercholesterolemia, elevated lipoprotein[a] and secondary dyslipidemias) should be excluded before considering primary statin resistance from rare genetic variants in lipoprotein-related or drug-metabolism genes. A wide variety of nonstatin lipid-lowering drugs are now available and can be added to statins to achieve more effective LDL-C lowering. Conclusions The evaluation of statin hyporesponsiveness is a multistep process that can lead to the optimization of lipid-lowering therapy for the prevention of ASCVD. It may also lead to the identification of distinct types of dyslipidemias that require specific therapies and/or the genetic screening of family members.